Novavax Financial Statements From 2010 to 2023

NVAX Stock  USD 7.31  0.18  2.52%   
Novavax financial statements provide useful quarterly and yearly information to potential Novavax investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Novavax financial statements helps investors assess Novavax's valuation, profitability, and current liquidity needs.
Operating Income
-644.7 M
Gross Profit
-156 M
Profit Margin
(0.37)
Net Interest Income
-19.9 M
Revenue
1.6 B
We have found one hundred two available fundamental ratios for Novavax, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Novavax last-minute market performance against the performance between 2010 and 2023 to make sure the company can sustain itself down the road. Novavax Revenue Per Employee is fairly stable at the moment as compared to the past year. Novavax reported Revenue Per Employee of 994,916 in 2022. Average Assets is likely to rise to about 2.7 B in 2023, whereas Net Income Per Employee is likely to drop (356.4 K) in 2023.

Novavax Revenues

2.14 Billion

Check Novavax financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novavax main balance sheet or income statement drivers, such as Direct Expenses of 876.5 M, Cost of Revenue of 1.1 B or Gross Profit of 1.2 B, as well as many exotic indicators such as Long Term Debt to Equity of 0.56, PPandE Turnover of 8.18 or Receivables Turnover of 6.21. Novavax financial statements analysis is a perfect complement when working with Novavax Valuation or Volatility modules.
  
This module can also supplement Novavax's financial leverage analysis and stock options assessment as well as various Novavax Technical models . Check out the analysis of Novavax Correlation against competitors. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Novavax Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Trade and Non Trade Receivables103.4 M82.4 M68.6 M
Slightly volatile
Property Plant and Equipment Net432.1 M400.5 M106.8 M
Slightly volatile
Trade and Non Trade Payables233.6 M216.5 M49.7 M
Slightly volatile
Liabilities Non Current371.3 M432.8 M222.8 M
Slightly volatile
Current Liabilities2.7 B2.5 B604.2 M
Slightly volatile
Total Liabilities3.1 B2.9 B833.9 M
Slightly volatile
Investments Non Current5.6 M5.6 M6.1 M
Slightly volatile
Investments Current195.6 M181.3 M98.6 M
Slightly volatile
Investments195.6 M181.3 M100 M
Slightly volatile
Inventory32.5 M36.7 M12.5 M
Slightly volatile
Goodwill and Intangible Assets112.6 M126.3 M75.3 M
Slightly volatile
Shareholders Equity USD(650.8 M)(634.1 M)(36 M)
Slightly volatile
Shareholders Equity Attributable to Parent(650.8 M)(634.1 M)(36 M)
Slightly volatile
Deferred Revenue592.9 M549.6 M224.1 M
Slightly volatile
Total Debt USD434.1 M549.8 M227.6 M
Slightly volatile
Debt Non Current229.1 M197.7 M193.4 M
Slightly volatile
Debt Current379.9 M352.1 M99.6 M
Slightly volatile
Total Debt434.1 M549.8 M227.6 M
Slightly volatile
Cash and Equivalents USD1.5 B1.3 B413.9 M
Slightly volatile
Cash and Equivalents1.5 B1.3 B413.9 M
Slightly volatile
Assets Non Current599.1 M555.3 M193.8 M
Slightly volatile
Current Assets1.8 B1.7 B601.7 M
Slightly volatile
Total Assets2.4 B2.3 B795.5 M
Slightly volatile
Accumulated Other Comprehensive Income(6.9 M)(6.4 M)(4.7 M)
Pretty Stable
Accounts Payable233.6 M216.5 M49.7 M
Slightly volatile
Receivables75.3 M82.4 M66 M
Slightly volatile
Inventories35.6 M33 M17 M
Slightly volatile

Novavax Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Income Tax Expense4.4 M4.3 M17.3 M
Slightly volatile
Weighted Average Shares Diluted84.4 M78.2 M29.9 M
Slightly volatile
Weighted Average Shares84.4 M78.2 M29.9 M
Slightly volatile
Selling General and Administrative Expense527.3 M488.7 M121.8 M
Slightly volatile
Research and Development Expense1.3 B1.2 B495.7 M
Slightly volatile
Revenues USD2.1 BB428.3 M
Slightly volatile
Revenues2.1 BB428.3 M
Slightly volatile
Operating Expenses1.9 B1.7 B616.9 M
Slightly volatile
Interest Expense16.3 M19.9 M9.1 M
Slightly volatile
Gross Profit1.2 B1.1 B291.1 M
Slightly volatile
Cost of Revenue1.1 BB737.6 M
Slightly volatile
Direct Expenses876.5 M812.4 M575.7 M
Slightly volatile

Novavax Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Share Based Compensation140.6 M130.3 M48.9 M
Slightly volatile
Effect of Exchange Rate Changes on Cash 4.9 M4.5 M414.8 K
Slightly volatile
Net Cash Flow from Operations(426.9 M)(415.9 M)(112.9 M)
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals195.6 M181.3 M23.1 M
Slightly volatile
Net Cash Flow from Investing(95.4 M)(93 M)(40.5 M)
Pretty Stable
Net Cash Flow from Financing319.5 M325 M231.9 M
Slightly volatile
Issuance Repayment of Debt Securities 88.1 M81.7 M5.6 M
Very volatile
Issuance Purchase of Equity Shares262 M248.6 M204.5 M
Slightly volatile
Net Cash Flow Business Acquisitions and Disposals(152.9 M)(149 M)(115.3 M)
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(184.1 M)(179.4 M)80 M
Pretty Stable
Depreciation Amortization and Accretion31.3 M29.1 M9.2 M
Slightly volatile
Capital Expenditure(95.4 M)(93 M)(25.1 M)
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Tangible Assets Book Value per Share25.4927.27418.4389
Slightly volatile
Sales per Share27.3525.3497.162
Slightly volatile
Return on Invested Capital0.980.903(0.3546)
Slightly volatile
Return on Average Equity1.831.696(0.1955)
Pretty Stable
Price to Sales Ratio0.420.40618.7284
Slightly volatile
Price to Book Value(1.38)(1.273)(4.4784)
Pretty Stable
Gross Margin0.810.5450.8111
Slightly volatile
Free Cash Flow per Share(7.02)(6.509)(6.5039)
Very volatile
Enterprise Value over EBITDA0.0820.076(8.4776)
Slightly volatile
Debt to Equity Ratio(4.92)(4.562)(6.7873)
Very volatile
Current Ratio0.710.6923.4405
Slightly volatile
Book Value per Share(8.32)(8.11)4.9098
Slightly volatile
Asset Turnover0.850.7940.2912
Slightly volatile
Total Assets Per Share22.2226.251520.1235
Slightly volatile
Cash Flow Per Share(5.22)(4.8342)(5.6693)
Pretty Stable
Receivables Turnover6.217.37625.105
Very volatile
Inventory Turnover2.752.632.8132
Slightly volatile
PPandE Turnover8.187.57972.8156
Slightly volatile
Cash and Equivalents Turnover1.51.38980.7651
Slightly volatile
Accounts Payable Turnover12.4511.5376.6172
Slightly volatile
Accrued Expenses Turnover2.523.13372.2075
Pretty Stable
Long Term Debt to Equity0.560.520.3683
Slightly volatile
Quick Ratio0.590.57382.8452
Slightly volatile
Net Current Assets as percentage of Total Assets(34.38)(33.4954)28.6692
Slightly volatile
Revenue to Assets0.950.87740.2656
Slightly volatile

Novavax Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Working Capital(776.5 M)(756.6 M)317.7 K
Slightly volatile
Tangible Asset Value2.3 B2.1 B718.5 M
Slightly volatile
Market Capitalization828.3 M807 M1.9 B
Slightly volatile
Invested Capital Average(720 M)(701.6 M)25.8 M
Slightly volatile
Invested Capital(1.2 B)(1.1 B)(56.5 M)
Slightly volatile
Free Cash Flow(522.3 M)(508.9 M)(137.9 M)
Slightly volatile
Enterprise Value(47.5 M)(46.3 M)1.7 B
Slightly volatile
Average Equity(398.1 M)(387.9 M)40.6 M
Slightly volatile
Average Assets2.7 B2.5 B795.5 M
Slightly volatile
Revenue Per Employee1.1 M994.9 K308.8 K
Slightly volatile

Novavax Fundamental Market Drivers

Forward Price Earnings0.5781
Cash And Short Term Investments1.3 B

Novavax Upcoming Events

14th of November 2023
Upcoming Quarterly Report
View
27th of February 2024
Next Financial Report
View
30th of September 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of June 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Novavax Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Novavax income statement, its balance sheet, and the statement of cash flows. Novavax investors use historical funamental indicators, such as Novavax's revenue or net income, to determine how well the company is positioned to perform in the future. Although Novavax investors may use each financial statement separately, they are all related. The changes in Novavax's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novavax's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novavax Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novavax. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2023
Deferred Revenue549.6 M592.9 M
Cost of RevenueB1.1 B
RevenuesB2.1 B
Revenue to Assets 0.88  0.95 
Revenue Per Employee994.9 K1.1 M

Novavax Investors Sentiment

The influence of Novavax's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novavax. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novavax's public news can be used to forecast risks associated with an investment in Novavax. The trend in average sentiment can be used to explain how an investor holding Novavax can time the market purely based on public headlines and social activities around Novavax. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novavax's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novavax's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novavax's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novavax.

Novavax Implied Volatility

    
  143.64  
Novavax's implied volatility exposes the market's sentiment of Novavax stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novavax's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novavax stock will not fluctuate a lot when Novavax's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novavax in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novavax's short interest history, or implied volatility extrapolated from Novavax options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Novavax using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out the analysis of Novavax Correlation against competitors. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide. Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Novavax Stock analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Global Correlations
Find global opportunities by holding instruments from different markets
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.90)
Revenue Per Share
19.149
Quarterly Revenue Growth
1.283
Return On Assets
(0.18)
Return On Equity
(8.98)
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.